Login

Financial Snapshot

Revenue
TTM
$0.00
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$22.11M
Current Assets
2025 Q4
Current Liabilities
2025 Q4
Current Ratio
2025 Q4
5.41%
Total Assets
2025 Q4
Total Liabilities
2025 Q4
$4.049M
Book Value
2025 Q4
$3.437M
Cash
2025 Q4
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$5.781M

Stock Price

Loading...
Market Cap: $10.741 Million

About Check Cap Ltd

Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule systems for colorectal cancer screening. Check Cap Ltd develops C-Scan, a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. Its capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps and other structural abnormalities. C-Scan is a non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.

Industry: X-Ray Apparatus & Tubes & Related Irradiation Apparatus Peers: Lifeward Ltd GlucoTrack Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support